Neuren Pharmaceuticals (ASX:NEU) Receives Priority Review Voucher Sale Proceeds
Financial Performance
Neuren Pharmaceuticals (ASX:NEU) has received one-third of the net proceeds from the sale of the Rare Pediatric Disease Priority Review Voucher. Partner Acadia Pharmaceuticals sold the PRV for US$150 million on December 11, 2024.
Operational Developments
The Priority Review Voucher was granted by the US FDA following the approval of DAYBUE™ (trofinetide) for Rett syndrome. Neuren is also advancing its drug candidate, NNZ-2591, with positive Phase 2 results in multiple neurodevelopmental disorders.
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.